國鴻氫能(09663.HK):中國證監會就公司擬實施H股全流通出具備案通知
格隆匯4月19日丨國鴻氫能(09663.HK)公吿,公司已收到中國證監會就公司建議實施H股全流通出具的日期為2024年4月18日的備案通知。根據備案通知,公司已就將不超過273,074,088股內資股(佔公司已發行股本總額約52.71%)轉換為可於聯交所上市及買賣的H股完成向中國證監會的備案。備案通知將自2024年4月18日起12個月內有效。公司將向聯交所上市委員會申請批准相關H股上市及買賣。
截至本公吿日期,公司就轉換及上市的實施計劃詳情尚未落實以及轉換及上市的完成須履行中國證監會、聯交所及其他相關境內外監管機構規定的其他相關程序。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.